This month's cover highlights the article RudLOV is an optically synchronized cargo transport method revealing unexpected effects of dynasore by Akiko K. Satoh, Takunori Satoh and colleagues. The ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, ...

If it comes to fruition, etavopivat will give Novo Nordisk a late-stage SCD programme to complement EPI01, an oral, fixed dose formulation of decitabine and tetrahydrouridine that is heading ...

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

休斯顿 - 市值310万美元的生物科技公司Bio-Path Holdings, Inc. (NASDAQ: BPTH )宣布其癌症治疗临床试验持续取得进展。根据InvestingPro数据显示，尽管该公司相对于债务维持着正现金状况，但其股票近几个月经历了显著波动。该公司针对实体瘤的BP1001-A的I/Ib期临床试验和针对急性髓系白血病 (AML)的prexigebersen ...

603833.SS Oppein Home Group Inc.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Genome-wide association studies (GWASs) have ...